These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31748528)

  • 1. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma.
    Okubo S; Kojima M; Matsuda Y; Hioki M; Shimizu Y; Toyama H; Morinaga S; Gotohda N; Uesaka K; Ishii G; Mino-Kenudson M; Takahashi S
    Sci Rep; 2019 Nov; 9(1):17145. PubMed ID: 31748528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
    Chatterjee D; Katz MH; Rashid A; Varadhachary GR; Wolff RA; Wang H; Lee JE; Pisters PW; Vauthey JN; Crane C; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Cancer; 2012 Jun; 118(12):3182-90. PubMed ID: 22028089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems.
    Vazzano J; Frankel WL; Wolfe AR; Williams TM; Chen W
    Hum Pathol; 2021 Mar; 109():1-11. PubMed ID: 33245985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microscopic tumor mapping of post-neoadjuvant therapy pancreatic cancer specimens to predict post-surgical recurrence: A prospective cohort study.
    Park Y; Han YB; Kim J; Kang M; Lee B; Ahn ES; Han S; Kim H; Na HY; Han HS; Yoon YS
    Pancreatology; 2024 Jun; 24(4):562-571. PubMed ID: 38556428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
    Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M
    Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
    Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
    Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
    Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
    JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy.
    Carpenter EL; Van Decar SG; McCarthy PM; Valdera FA; Adams AM; O'Shea AE; Smolinsky T; Thomas K; Clifton GT; Newhook TE; Peoples GE; Nelson DW; Vreeland TJ
    J Surg Oncol; 2024 Jul; 130(1):109-116. PubMed ID: 38801055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.
    Murthy P; Zenati MS; Al Abbas AI; Rieser CJ; Bahary N; Lotze MT; Zeh HJ; Zureikat AH; Boone BA
    Ann Surg Oncol; 2020 Mar; 27(3):898-906. PubMed ID: 31792715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy.
    Cools KS; Sanoff HK; Kim HJ; Yeh JJ; Stitzenberg KB
    J Surg Oncol; 2018 Sep; 118(3):455-462. PubMed ID: 30114330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection.
    Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada YU; Kumamoto T; Endo I
    Anticancer Res; 2019 Aug; 39(8):4431-4440. PubMed ID: 31366541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes.
    Zhang ML; Kem M; Rodrigues C; Sandini M; Ciprani D; Hank T; Kunitoki K; Qadan M; Ferrone C; Lillemoe K; Fernández-Del Castillo C; Mino-Kenudson M
    Histopathology; 2020 Jul; 77(1):144-155. PubMed ID: 31965618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.
    Lee SM; Katz MH; Liu L; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
    Am J Surg Pathol; 2016 Dec; 40(12):1653-1660. PubMed ID: 27631521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual Tumor Index: A Prognostically Significant Pathologic Parameter in Neoadjuvant-treated Pancreatic Ductal Adenocarcinoma.
    Panni RZ; Gonzalez I; Hartley CP; Williams GA; Liu J; Hawkins WG; Chatterjee D
    Am J Surg Pathol; 2018 Nov; 42(11):1480-1487. PubMed ID: 30179901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
    Taherian M; Wang H
    Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.
    Nejati R; Goldstein JB; Halperin DM; Wang H; Hejazi N; Rashid A; Katz MH; Lee JE; Fleming JB; Rodriguez-Canales J; Blando J; Wistuba II; Maitra A; Wolff RA; Varadhachary GR; Wang H
    Pancreas; 2017 Oct; 46(9):1180-1187. PubMed ID: 28902789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
    Kim SS; Ko AH; Nakakura EK; Wang ZJ; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Kim GE
    Am J Surg Pathol; 2019 Mar; 43(3):334-340. PubMed ID: 30211728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma.
    Kameyama A; Ye J; Shimomura A; Yokohira M; Nakano-Narusawa Y; Yamakawa K; Mukai Y; Sanomura T; Okuyama H; Miyatake N; Furihata M; Tanaka C; Kitazawa R; Bando Y; Suemitsu Y; Kojima M; Mino-Kenudson M; Suzuki Y; Okano K; Matsuda Y
    Pancreatology; 2021 Dec; 21(8):1506-1515. PubMed ID: 34563448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.